QIAGEN to discontinue NeuMoDx integrated PCR testing system, support customers during transition period

Venlo, the Netherlands, June 06, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a decision to discontinue the NeuMoDx 96 and 288 Molecular Systems in light of the market development trends for these product lines following the COVID-19 pandemic and changing customer needs for integrated PCR-based clinical molecular testing systems. QIAGEN understands the impact of this decision on its customers and will continue to provide support for existing NeuMoDx users durin ...